Table 13.

—[Sections 4.1.1-4.3.5] High-Dose Aspirin vs Low-Dose Aspirin for 30 Days Post PCI⁷⁸

Outcomes	Participants (studies), Follow-up	Quality of the Evidence (GRADE)	Relative Effect (95% CI)a	Anticipated Absolute Effects Over 30 d
				Risk With Aspirin 75-100 mg	Risk Difference With Aspirin 300-325 mg (95% CI)
Total mortalityb	17,236 (1 RCT), 30 d	Moderate due to imprecisionc	RR 0.87 (0.74-1.03)	25 per 1,000d	No significant difference; 3 fewer per 1,000 (from 7 fewer to 1 more)
MI nonfatal events	17,236 (1 RCT), 30 d	Moderate due to imprecisionc	RR 0.97 (0.82-1.16)	21 per 1,000d	No significant difference; 1 fewer per 1,000 (from 4 fewer to 3 more)
Strokee	17,236 (1 RCT), 30 d	Moderate due to imprecisionc	RR 1.19 (0.84-1.68)	5 per 1,000d	No significant difference; 1 more per 1,000 (from 1 fewer to 3 more)
Major extracranial bleedf	17,236 (1 RCT), 30 d	Moderate due to imprecisionc	RR 1.09 (0.89-1.34)	14 per 1,000d	No significant difference; 1 more per 1,000 (from 2 fewer to 5 more)

CURRENT-OASIS 7 = Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions; TIMI = Thombolysis in Myocardial Infarction. See Table 1-3 legends for expansion of other abbreviations.

^aStudy reports hazard ratios. We have converted to relative risks (RR) for consistency.

^bOf the total deaths in the CURRENT-OASIS 7 study, nine of 314 (2.9%) with low-dose aspirin and 10 of 273 (2.7%) with higher-dose aspirin were fatal bleeding events.

^cWide CIs suggest benefit and harm with high-dose aspirin.

^dControl group risk estimates come from event rates in patients allocated to low-dose aspirin undergoing PCI in CURRENT-OASIS 7.

^eIt is unclear from the article whether hemorrhagic and fatal strokes were included in total strokes.

^fTIMI criteria used. It is unclear from the article whether hemorrhagic and fatal bleeding were included in total major bleeding.